Taking a Healthy Interest in You
An agency of the Ministry of Health
ISO 9001:2008 Certified

Documents & Forms

NHF Adds 2 New Active Ingredients And Removes 2 Others From Its Individual Benefits Drug List

The National Health Fund (NHF) has added two new active ingredients to its Drug List.


They are Insulin Detemir and Levetiracetam, which treat diabetes and epilepsy respectively. Insulin Detemir under the label Levemir Flexpen has a subsidy of $4,875.80 for a pack of five (5) 3ml insulin pens. Levetiracetam under the label Keppra has a subsidy of $3,796 for each 300milliliter 10% solution and $64 per 500milligram tablet.

Two other active ingredients were also removed from the NHF and JADEP Drug Lists. They are Rosiglitazone (Avandia) and combination of rosiglitazone and metformin (Avandamet) used for the treatment of diabetes. These drugs were removed from the programme due to clinical studies, which revealed an association with Rosiglitazone and a significantly increased risk of cardiovascular disease (heart attacks and heart failure) especially in high risk patients. Consequently, Rosiglitazone and its combinations were removed from a number of pharmaceutical markets worldwide, and in markets where the drug was allowed to remain, restriction of use was imposed.

In addition two new labels were also added to the NHF Drug list. They are Glimepiride-H2K (Glimepiride) 2mg Tablets with a subsidy of $29.31 per tablet for the treatment of Diabetes and Resilo-H (Losartan + Hydrochlorothiazide) Tablets 50mg/12.5mg with a subsidy of $41.17 per tablet, for the treatment of Hypertension and as an adjunct for Diabetes.

Details of the NHF subsidies for these items are available from NHF Participating Pharmacies, the NHF website or by calling NHF.

For further information contact:

Rosemarie Lee, Tel. 906-1106

Shermaine Robotham, Tel. 322- 0809